Zavesca

Active Ingredient(s): Miglustat
FDA Approved: * July 31, 2003
Pharm Company: * ACTELION PHARMS
Category: Enzymes

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Zavesca Overview

Miglustat (OGT 918, N-butyl-deoxynojirimycin) is a drug developed by Oxford GlycoSciences and marketed by Actelion and is used primarily to treat type I Gaucher disease (GD1). It is marketed under the trade name Zavesca. Contents 1 Medical uses 2 Contraindications 3 Adverse effects 4 Mechanism of action 5 Chemistry 6 Research 7 See also 8 References Medical uses Miglustat is used to treat adults with mild-to-moderate type I Gaucher disease for whom enzyme replacement therapy is unsui...

Read more Zavesca Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Miglustat

Recent Zavesca Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

NDC Database Records for Zavesca: (1 result)

Sorted by National Drug Code

• 66215-201 Zavesca 100 mg Oral Capsule by Actelion Pharmaceuticals Us, Inc.

Other drugs which contain Miglustat or a similar ingredient: (1 result)

• MIGLUSTAT

Related Zavesca Topics: